Literature DB >> 16673107

[Sonography of enlarged lymph nodes: Pathogenetic categorization using contrast enhanced power Doppler sonography].

B M Stoeckelhuber1, M Wiesmann, S A Berg, M Tronnier, M Stoeckelhuber, S Krueger, J Gellissen, C U Bergmann-Koester.   

Abstract

BACKGROUND: The purpose of this study was to categorize enlarged superficial lymph nodes as benign or malignant using sonomorphologic features and vascularization pattern. PATIENTS AND METHODS: Enlarged superficial lymph nodes in 57 patients were assessed with B-mode and contrast-enhanced power Doppler sonography. Morphology and vascularization were evaluated. The lymph nodes were categorized as benign or malignant. Correlation was made with histology and follow-up results.
RESULTS: In 55 patients, 40 lymph nodes were correctly categorized as benign and 15 lymph nodes correctly as malignant. The most reliable criteria were shape and vascularization pattern. Intact hilar vessels and branching indicated benign enlargement, destruction of the hilum with vessels running peripherally along the capsule indicated metastatic destruction. Two benign lymph nodes were considered malignant (false positive).
CONCLUSION: B-mode ultrasound along with contrast-enhanced power Doppler ultrasound is an easy, cost-effective, and reliable tool for differentiation and categorization of enlarged superficial lymph nodes.

Entities:  

Mesh:

Year:  2006        PMID: 16673107     DOI: 10.1007/s00105-006-1152-5

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  15 in total

1.  [Experiences with using the ultrasound contrast medium levovist in differentiation of cervical lymphomas with color-coded duplex ultrasound].

Authors:  G Schade
Journal:  Laryngorhinootologie       Date:  2001-04       Impact factor: 1.057

2.  [The magnetic resonance tomographic differential diagnosis between reactively enlarged lymph nodes and cervical lymph node metastases].

Authors:  H J Steinkamp; T Heim; P Schubeus; W Schörner; R Felix
Journal:  Rofo       Date:  1992-10

3.  [Cervical lymph node metastases. The sonographic demonstration of malignancy].

Authors:  H J Steinkamp; N Hosten; R Langer; F Mathe; C Ehritt; R Felix
Journal:  Rofo       Date:  1992-02

Review 4.  [High resolution small parts sonography (7.5 MHz) of the head and neck region].

Authors:  W Dewes; N Gritzmann; A Hirschner; D Koischwitz
Journal:  Radiologe       Date:  1996-01       Impact factor: 0.635

5.  Lymph node metastases of cutaneous melanoma: diagnosis by B-scan and color Doppler sonography.

Authors:  M Moehrle; A Blum; G Rassner; M Juenger
Journal:  J Am Acad Dermatol       Date:  1999-11       Impact factor: 11.527

6.  [Value of sonomorphologic criteria in the identification of regional metastases of squamous cell cancers of the ENT area].

Authors:  M C Grasl; K Neuwirth-Riedl; N Gritzmann; H Schurawitzki; O Braun
Journal:  HNO       Date:  1989-08       Impact factor: 1.284

7.  Sonography of abnormal lymph nodes in vitro: correlation of sonographic and histologic findings.

Authors:  L Rubaltelli; E Proto; R Salmaso; P Bortoletto; F Candiani; P Cagol
Journal:  AJR Am J Roentgenol       Date:  1990-12       Impact factor: 3.959

8.  Assessment of vascularity in reactive lymph nodes by means of D-galactose contrast-enhanced Doppler sonography.

Authors:  C Willam; J Mäurer; R Schroeder; N Hidajat; B Hell; J Bier; S Weber; R Felix
Journal:  Invest Radiol       Date:  1998-03       Impact factor: 6.016

9.  Lymph node metastases in patients with cutaneous melanoma: improvements in diagnosis by signal-enhanced color Doppler sonography.

Authors:  Monika-Hildegard Schmid-Wendtner; Dorothee Dill-Müller; Jens Baumert; Arnold Wagner; Julia Eberle; Wolfgang Tilgen; Gerd Plewig
Journal:  Melanoma Res       Date:  2004-08       Impact factor: 3.599

10.  Cervical lymphadenopathy: ratio of long- to short-axis diameter as a predictor of malignancy.

Authors:  H J Steinkamp; M Cornehl; N Hosten; W Pegios; T Vogl; R Felix
Journal:  Br J Radiol       Date:  1995-03       Impact factor: 3.039

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.